KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Trajectories and predictors of depressive and anxiety symptom improvement with adjunctive cariprazine in antidepressant-treated adults with major depression: A Bayesian mega-analysis of two randomized trials.

Jeffrey R Strawn, Jeffrey A Mills

J Affect Disord 394(Pt B) 120657

PMID41224012
PMCID-
DOI10.1016/j.jad.2025.120657
发表日期2025-11-12
摘要

摘要

BACKGROUND: Adjunctive cariprazine improves depressive symptoms in antidepressant-treated adults with major depressive disorder (MDD); however, how improvement in both anxiety and depressive symptoms varies across individuals and how to predict improvement with adjunctive cariprazine is unknown. METHODS: We conducted a mega-analysis of individual participant data (N = 1501) from two multicenter, double-blind, placebo-controlled phase 3 trials comparing adjunctive cariprazine 1.5 mg/day, 3 mg/day, and placebo in individuals receiving stable antidepressant treatment. The primary outcome was change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores; secondary outcomes included Clinical Global Impressions-Improvement (CGI-I) and Hamilton Anxiety Rating Scale (HAM-A) scores. Bayesian logarithmic trend models were used to characterize individual response trajectories and identify predictors of response. RESULTS: Adjunctive cariprazine produced greater improvement in depressive symptoms (vs. placebo) at both 1.5 mg/day (β = -0.319, p < 0.001) and 3 mg/day (β = -0.233, p = 0.002). Early improvement by week 2 predicted continued improvement across the 6-week trial. Greater baseline depression severity predicted a larger response (β = -0.075, p < 0.001), while more anxious patients had a smaller reduction in MADRS scores (β = 0.120, p < 0.001). Women (β = -0.190, p = 0.006) and those using SSRIs (β = -0.478, p < 0.001) also had greater improvement. For anxiety, higher baseline HAM-A scores predicted more improvement over time (β = -0.250, p < 0.001), while more severe baseline depression was associated with less anxiety improvement (β = 0.162, p < 0.001). Cariprazine 1.5 mg/day, but not 3 mg/day, modestly improved HAM-A scores relative to placebo (β = -0.147, p = 0.043). CONCLUSIONS: This mega-analysis highlights how variability in symptom trajectories with adjunctive cariprazine can be leveraged clinically to understand differences in response. These findings support using early symptom change and individual patient characteristics to inform clinical decision-making and tailor adjunctive treatment strategies.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。